e.g. mhealth
Search Results (1 to 2 of 2 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 1 JMIR Formative Research
- 1 JMIR Research Protocols
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Hence, a new organizational scheme has been proposed for patients treated with emicizumab (Hemlibra) [13] in France.
Since June 15, 2021, community pharmacists have played an important role in the care pathway with the implementation of a dual circuit of dispensing, providing the patient the freedom to choose the site from which to pick up emicizumab: hospital or community pharmacy.
JMIR Form Res 2024;8:e54656
Download Citation: END BibTex RIS
In 2019, emicizumab received marketing authorization for severe hemophilia A with or without an inhibitor in Europe [16]. This drug was initially available only from French hospital pharmacies, but from June 15, 2021, it has also been available in community pharmacies.
JMIR Res Protoc 2023;12:e43091
Download Citation: END BibTex RIS